关键词: font-size:medium, ">2型糖尿病；瑞格列奈；阿卡波糖；Meta分析

Abstract: Objective：To evaluate the efficacy and safety of repaglinide combined with acarbose in the treatment of type 2 diabetes mellitus(T2DM)， and to provide evidence-based reference for the clinic. Methods：Retrieved from CNKI， VIP， Wanfang， PubMed， Embase and Cochrane Library， randomized controlled trials(RCT) about efficacy and safety of repaglinide+acarbose(trial group： R+A group) versus other options [control group： containing repaglinide(R group)， acarbose(A group) and repaglinide+metformin(R+M group)] in the treatment of T2DM were collected. Meta-analysis was performed by RevMan5.4 statistical software after data extraction. Results： a total of 24 studies including 2081 patients were included. In terms of efficacy， the reduction effect of 2hPG， FPG and HbA1c in R+A group was significantly better than control group(P<0.001)， and the markedly effective rate and total effective rate were significantly higher(P<0.001). There was no statistical difference in the effective rate(P>0.05). The results of subgroup analysis performed by intervention measures were consistent with overall analysis. In terms of safety， the incidence of gastrointestinal ADR in R+A group was lower than control group(P<0.05). There was no statistical difference in the incidence of hypoglycemia(P>0.05). The results of subgroup analysis were consistent with overall analysis， except that there was no statistical difference in the incidence of gastrointestinal ADR between R+A group and R group（P=0.05）. Conclusion： Repaglinide combined with acarbose can enhance the curative effect without increasing hypoglycemia， and can reduce the incidence of gastrointestinal adverse reactions.

Key words: font-size:medium, ">Type 2 diabetes mellitus； Repaglinide； Acarbose； Meta-analysis